BriaCell Therapeutics Management

Management criteria checks 2/4

BriaCell Therapeutics' CEO is Bill Williams, appointed in Oct 2016, has a tenure of 7.92 years. total yearly compensation is $1.22M, comprised of 60.6% salary and 39.4% bonuses, including company stock and options. directly owns 0.49% of the company’s shares, worth $116.24K. The average tenure of the management team and the board of directors is 7.9 years and 5.5 years respectively.

Key information

Bill Williams

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage	60.6%
CEO tenure	7.9yrs
CEO ownership	0.5%
Management average tenure	7.9yrs
Board average tenure	5.5yrs

Recent management updates

Recent updates

BriaCell stock rises on license deal for anti-cancer agent

Aug 04

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

Jul 05

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

Jun 29

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises

Jun 10

BriaCell Therapeutics skyrockets 104% on robust overall survival benefit in advanced breast cancer patients

Jun 02

CEO Compensation Analysis

How has Bill Williams's remuneration changed compared to BriaCell Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Apr 30 2024	n/a	n/a	-US$6m
Jan 31 2024	n/a	n/a	-US$13m
Oct 31 2023	n/a	n/a	-US$13m
Jul 31 2023	US$1m	US$737k	-US$20m
Apr 30 2023	n/a	n/a	-US$18m
Jan 31 2023	n/a	n/a	-US$23m
Oct 31 2022	n/a	n/a	-US$412k
Jul 31 2022	US$811k	US$561k	-US$27m
Apr 30 2022	n/a	n/a	-US$42m
Jan 31 2022	n/a	n/a	-US$30m
Oct 31 2021	n/a	n/a	-US$41m
Jul 31 2021	US$830k	US$218k	-US$14m
Apr 30 2021	n/a	n/a	US$2m
Jan 31 2021	n/a	n/a	-US$2m
Oct 31 2020	n/a	n/a	-US$3m
Jul 31 2020	US$231k	US$231k	-US$4m
Apr 30 2020	n/a	n/a	-US$4m
Jan 31 2020	n/a	n/a	-US$5m
Oct 31 2019	n/a	n/a	-US$5m
Aug 01 2019	n/a	n/a	-US$5m
Apr 30 2019	n/a	n/a	-US$5m
Jan 31 2019	n/a	n/a	-US$5m
Oct 31 2018	n/a	n/a	-US$4m
Jul 31 2018	US$228k	US$175k	-US$4m

Compensation vs Market: Bill's total compensation ($USD1.22M) is above average for companies of similar size in the US market ($USD677.23K).

Compensation vs Earnings: Bill's compensation has increased whilst the company is unprofitable.

CEO

Bill Williams (69 yo)

7.9yrs

Tenure

US$1,215,514

Compensation

Dr. William V. Williams, M.D., FRCP, also known as Bill, has been the Chief Executive Officer and President of BriaCell Therapeutics Corp. since October 2016 and serves as its Director Since November 11, 2...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
William Williams	CEO, President & Director	7.9yrs	US$1.22m	0.49% $ 116.2k
Gadi Levin	CFO & Corporate Secretary	8.6yrs	US$391.44k	0.0092% $ 2.2k
Miguel Lopez-Lago	Chief Scientific Officer	2.3yrs	US$368.44k	0% $ 0
Giuseppe Del Priore	Chief Medical Officer	2.6yrs	US$948.90k	0% $ 0
Charles Wiseman	Founder	9.3yrs	US$241.14k	no data

7.9yrs

Average Tenure

62yo

Average Age

Experienced Management: BCTX's management team is seasoned and experienced (7.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
William Williams	CEO, President & Director	7.8yrs	US$1.22m	0.49% $ 116.2k
Charles Wiseman	Founder	3.7yrs	US$241.14k	no data
Brian Metcalf	Member of Scientific Advisory Board	7.3yrs	no data	no data
Marc Lustig	Independent Director	3yrs	US$163.44k	8.28% $ 2.0m
Martin Schmieg	Independent Director	3.8yrs	US$170.94k	0.0019% $ 446.1
Rebecca Taub	Independent Director	5.5yrs	US$95.44k	0% $ 0
Vaughn Embro-Pantalony	Lead Independent Director	5.5yrs	US$187.23k	0.031% $ 7.4k
Douglas Faller	Member of Scientific Advisory Board	7.3yrs	no data	no data
Thomas Kieber-Emmons	Member of Scientific Advisory Board	7.3yrs	no data	no data
Maria Trojanowska	Member of Scientific Advisory Board	7.3yrs	no data	no data
Jamieson Bondarenko	Independent Chairman of the Board	5.6yrs	US$677.08k	0.39% $ 93.1k
Cara Haymaker	Member of Scientific Advisory Board	5yrs	no data	no data

5.5yrs

Average Tenure

68yo

Average Age

Experienced Board: BCTX's board of directors are considered experienced (5.5 years average tenure).

BriaCell Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Independent Director recently bought US$2.0m worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

Independent Chairman of the Board recently bought US$118k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

High number of new directors

Recent updates

Price target decreased by 14% to US$15.00

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

New major risk - Financial data availability

New major risk - Shareholder dilution

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $8.50425 million.

BriaCell Therapeutics Corp. Announces Positive Overall Survival Data of its Phase 2 Clinical Study of Bria-IMT in Combination with an Immune Check Point Inhibitor

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+ for Prostate Cancer

BriaCell Therapeutics Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

BriaCell Therapeutics Corp. Quadruples Progression Free Survival (Pfs) in Patient with "Eye-Bulging" Metastatic Breast Cancer

BriaCell Therapeutics Receives Letter from Nasdaq Due to Non-Compliance with the Minimum Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2)

Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024

BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer

New minor risk - Shareholder dilution

Independent Director recently bought US$2.0m worth of stock

BriaCell Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.80586 million.

BriaCell Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

New major risk - Negative shareholders equity

BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing

BriaCell Therapeutics Corp. Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset

BriaCell Therapeutics Corp. Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Therapeutics Corp., Annual General Meeting, Jan 30, 2024

BriaCell Therapeutics Corp. Announces Anew Remarkable Responder in Phase 2 Study of the Bria-IMT Combination Regimen

BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS™ IND

New minor risk - Share price stability

New major risk - Financial position

BriaCell Therapeutics Corp. Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate

BriaCell Therapeutics Corp. Initiates Pivotal Phase 3 Study of Bria-Imt™ in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. completed the Spin-Off of 33.33% stake in Pre-Clinical Assets of BriaCell Therapeutics Corp.

Briacell Receives National Cancer Institute Grant to Advance Its Bria-Ots™ Immunotherapy for Cancer

FDA Approves BriaCell’s Pivotal Registrational Study Design in Advanced Metastatic Breast Cancer

BriaCell Therapeutics Corp. Announces Positive End of Phase II Meeting with the FDA for Bria-IMT™ Combination in Advanced Metastatic Breast Cancer

Independent Chairman of the Board recently bought US$118k worth of stock

BriaCell Therapeutics Corp., Annual General Meeting, Jan 24, 2023

BriaCell Therapeutics Corp. Reports Positive Breast Cancer Efficacy Data with Bria-IMT™ Immunotherapy Treatment at SITC Annual Meeting

BriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation Progressing

BriaCell Therapeutics Corp. Announces New Clinical Trial Site to Bring Novel Cancer Treatments to Advanced Breast Cancer Patients

BriaCell Therapeutics Corp. Secures License for A Promising Novel Anti-Cancer Agent

BriaCell stock rises on license deal for anti-cancer agent

BriaCell partners with Waisman Biomanufacturing to make & supply prostate cancer therapy

BriaCell, Harvard enter research agreement to identify targets for cancer treatments

BriaCell Therapeutics Corp. Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Advances Preparatory Work for New Bria-OTS Breast Cancer Clinical Trial

High number of new directors

BriaCell Therapeutics Corp. Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

BriaCell Therapeutics Corp. Appoints Alexander Kharazi to Its Scientific Advisory Board

Director recently bought US$433k worth of stock

Briacell Therapeutics Corp. Appoints Giuseppe Del Priore as Chief Medical Officer

Director recently bought US$355k worth of stock

BriaCell Therapeutics Corp.(TSXV:BCT) dropped from S&P/TSX Venture Composite Index

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

BriaCell Therapeutics Corp. Announces Phase I/IIa Clinical Trial Combination Study in Advanced Breast Cancer Patients Open for Enrollment

Investor sentiment improved over the past week

Briacell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers

BriaCell Therapeutics receives proceed of $12.88M from warrant exercises

BriaCell Therapeutics Corp. announced that it has received $27.195924 million in funding